Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tipifarnib in Treating Young Patients With Refractory Leukemia

This study has been completed.
Sponsor:
Collaborators:
Children's Oncology Group
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00022451
First received: August 10, 2001
Last updated: March 14, 2012
Last verified: March 2012